-
Nutrition and Cancer 2020: Dysgeusia can be found in 50% of cancer patients undergoing chemotherapy. Nonetheless, dysgeusia can be present in treatment-naïve patients, and may negatively impact...
: Dysgeusia can be found in 50% of cancer patients undergoing chemotherapy. Nonetheless, dysgeusia can be present in treatment-naïve patients, and may negatively impact nutrition and quality of life.: Treatment-naïve non-small cell lung cancer (NSCLC) was assessed for dysgeusia using a self-reporting questionnaire and a rinse stimuli technique. Patients were evaluated in terms of health-related quality of life (HRQL) using the EORTC-QLQ-C30 questionnaire and in terms of nutrition using the subjective global assessment (SGA), energy consumption and body composition.: Among 65 treatment-naïve patients, dysgeusia was self-reported in 35%. Using the rinse stimuli technique, most of the patients perceived taste stimuli with a minimal concentration, but could not recognize the taste. Patients with dysgeusia presented significantly less lean-body mass ( = 0.027), and higher fat mass ( = 0.027). Additionally, these patients had significantly more gastrointestinal symptoms including nausea ( = 0.042), anorexia ( = 0.004), and early satiety ( < 0.0001). Dysgeusia was also associated with less food consumption ( = 0.010). Last, patients with dysgeusia had clinically-significant alterations in HRQL scales.: Presence of dysgeusia in NSCLC patients before undergoing chemotherapy is associated with worse nutritional outcomes. The routine assessment of dysgeusia in treatment-naïve patients should be encouraged to timely assess and follow nutritional parameters.
Topics: Anorexia; Carcinoma, Non-Small-Cell Lung; Dysgeusia; Female; Humans; Incidence; Lung Neoplasms; Male; Mexico; Middle Aged; Nausea; Nutritional Status; Quality of Life; Self Report; Surveys and Questionnaires
PubMed: 31259622
DOI: 10.1080/01635581.2019.1633362 -
Gastroenterology Sep 2020
Meta-Analysis
Topics: Betacoronavirus; COVID-19; Coronavirus Infections; Dysgeusia; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2
PubMed: 32387496
DOI: 10.1053/j.gastro.2020.05.003 -
Southern Medical Journal Dec 2008
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Dysgeusia; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Paraneoplastic Syndromes; Sodium Chloride, Dietary
PubMed: 19005446
DOI: 10.1097/SMJ.0b013e31818bbfd3 -
Annals of Cardiac Anaesthesia 2022Various drugs, including anesthetic agents, can cause parosmia in the perioperative period. There are reported cases of patients with alterations of smell and taste due...
Various drugs, including anesthetic agents, can cause parosmia in the perioperative period. There are reported cases of patients with alterations of smell and taste due to local anesthetics, nerve damage, or as a side effect of general anesthesia. We present a case of a 58-year-old male who developed parosmia and dysgeusia in the postoperative period after radical nephrectomy and inferior vena cava thrombectomy. The anesthetics used were fentanyl and propofol for general anesthesia and ropivacaine for epidural analgesia. Clinical examination did not reveal any pathology.
Topics: Anesthesia, General; Anesthesia, Intravenous; Anesthetics, Intravenous; Anesthetics, Local; Dysgeusia; Fentanyl; Humans; Male; Middle Aged; Olfaction Disorders; Pain, Postoperative; Propofol
PubMed: 35075034
DOI: 10.4103/aca.ACA_93_21 -
Infectious Diseases (London, England) Mar 2021
Topics: COVID-19; Contact Tracing; Dysgeusia; Humans; Olfaction Disorders; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2
PubMed: 33287593
DOI: 10.1080/23744235.2020.1854849 -
Attributes of dysgeusia and anosmia of coronavirus disease 2019 (COVID-19) in hospitalized patients.Oral Diseases Apr 2022While chemosensory dysfunctions, dysgeusia and anosmia/hyposmia, are recognized as distinctive symptoms of COVID-19, their temporality of presentation and association...
OBJECTIVES
While chemosensory dysfunctions, dysgeusia and anosmia/hyposmia, are recognized as distinctive symptoms of COVID-19, their temporality of presentation and association with the patient age, gender, disease severity, and comorbidities has been sparsely studied. Hence, we evaluated the latter associations of chemosensory dysfunction, in hospitalized COVID-19 patients in the United Arab Emirates (UAE).
MATERIALS AND METHODS
Information on chemosensory dysfunction and history of chronic systemic comorbidities, if any, was obtained from 149 COVID-19 patients in an infectious disease hospital in UAE, using their medical records, as well as from a face-to-face questionnaire survey. Additionally, a modified SNOT-22 questionnaire that measures disease-specific quality of life in patients with upper respiratory tract affections was also administered.
RESULTS
Chemosensory dysfunction was reported by 94.6% of the cohort, and anosmia with dysgeusia was significantly more in males than females with severe COVID-19. Males with moderate COVID-19 and systemic comorbidities were more likely to present with chemosensory dysfunction in comparison with females. SNOT-22 questionnaire revealed that nasal blockage and runny nose were more prevalent in mild/moderate, than in the severe, state of COVID-19.
CONCLUSION
Our data confirm the commonality of chemosensory dysfunction during COVID-19 progression, and the significantly more pronounced combined dysfunction in males with severe COVID-19, and comorbidities.
Topics: Anosmia; COVID-19; Dysgeusia; Female; Humans; Male; Quality of Life; United Arab Emirates
PubMed: 33176049
DOI: 10.1111/odi.13713 -
Archives of Otolaryngology--head & Neck... Sep 1996Dysgeusia, distortion of taste perception, is a debilitating disorder that affects thousands of Americans. Presently, most forms of dysgeusia are considered to be...
BACKGROUND
Dysgeusia, distortion of taste perception, is a debilitating disorder that affects thousands of Americans. Presently, most forms of dysgeusia are considered to be untreatable, and no data are available for counseling patients on the probability of recovery.
OBJECTIVE
To examine the probability of resolution of symptoms among patients with dysgeusia who were evaluated at the University of Pennsylvania Smell and Taste Center, Philadelphia, from January 1989 to December 1994.
DESIGN
In this retrospective study, 117 patients with primary complaints of dysgeusia were initially identified from a population of 429 patients with smell and taste disorders who were seen during this period.
PARTICIPANTS
Forty-eight patients agreed to participate. Each patient completed a telephone interview and a questionnaire that contained a dysgeusia severity rating scale, medical health questions, and the Beck Depression Inventory.
RESULTS
Two thirds of the patients experienced spontaneous resolution of the dysgeusia, with the average duration being 10 months. A distinct relationship between the resolution of dysgeusia and depression was identified.
CONCLUSION
These findings, along with the evidence that some dysgeusias are treatable, bode well for a disorder that was heretofore considered by many physicians as unrelenting.
Topics: Aged; Dysgeusia; Female; Humans; Male; Middle Aged; Remission, Spontaneous
PubMed: 8797560
DOI: 10.1001/archotol.1996.01890210037009 -
CMAJ : Canadian Medical Association... Jun 2020Anosmia and dysgeusia have been reported as potential symptoms of coronavirus disease 2019. This study aimed to confirm whether anosmia and dysgeusia are specific...
BACKGROUND
Anosmia and dysgeusia have been reported as potential symptoms of coronavirus disease 2019. This study aimed to confirm whether anosmia and dysgeusia are specific symptoms among those who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
METHODS
We conducted an age-matched case-control study in the Eastern Townships region of Quebec between Mar. 10 and Mar. 23, 2020. We included adults (age ≥ 18 yr) who tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction. Cases were matched (1:1) according to 5-year age groups with control patents selected randomly from among all patients who tested negative for SARS-CoV-2 during the same period. Demographic and laboratory information was collected from medical records. Clinical symptoms and comorbidities associated with anosmia and dysgeusia were obtained by telephone interview with a standardized questionnaire.
RESULTS
Among 2883 people tested for SARS-CoV-2, we identified 134 positive cases (70 women [52.2%] and 64 men [47.8%]; median age 57.1 [interquartile range 41.2-64.5] yr). The symptoms independently associated with SARS-CoV-2 positivity in conditional logistic regression were anosmia or dysgeusia or both (adjusted odds ratio [OR] 62.9, 95% confidence interval [CI] 11.0-359.7), presence of myalgia (adjusted OR 7.6, 95% CI 1.9-29.9), blurred vision (adjusted OR 0.1, 95% CI 0.0-0.8) and chest pain (adjusted OR 0.1, 95% CI 0.0-0.6).
INTERPRETATION
We found a strong association between olfactory and gustatory symptoms and SARS-CoV-2 positivity. These symptoms should be considered as common and distinctive features of SARS-CoV-2 infection and should serve as an indication for testing and possible retesting of people whose first test result is negative.
Topics: Adult; Aged; Betacoronavirus; COVID-19; COVID-19 Testing; Case-Control Studies; Clinical Laboratory Techniques; Coronavirus Infections; Dysgeusia; Female; Humans; Male; Middle Aged; Olfaction Disorders; Pandemics; Pneumonia, Viral; Quebec; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; SARS-CoV-2
PubMed: 32461325
DOI: 10.1503/cmaj.200869 -
The Canadian Journal of Neurological... Nov 2020Dysgeusia is a frequent, yet underreported side effect of chemotherapy for cancer. We report here the first use of gabapentin in two glioblastoma patients who developed...
Dysgeusia is a frequent, yet underreported side effect of chemotherapy for cancer. We report here the first use of gabapentin in two glioblastoma patients who developed dysgeusia following intra-arterial administration of carboplatin or oral administration of lomustine, respectively. Treatment initiation was followed by resolution of taste alteration within weeks. Both patients reported significant improvement in their quality of life and regained weight, allowing further chemotherapy cycles. We hypothesized that in these two cases, chemotherapy impeded gustatory cells turnover and function, resulting in a gustatory "deafferentation-like" syndrome which was successfully addressed by the medication.
Topics: Administration, Oral; Dysgeusia; Gabapentin; Glioblastoma; Humans; Quality of Life
PubMed: 32498727
DOI: 10.1017/cjn.2020.115 -
F1000Research 2021: The present study aimed to determine the global prevalence of anosmia and dysgeusia in coronavirus disease 2019 (COVID-19) patients and to assess their association... (Meta-Analysis)
Meta-Analysis
Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis.
: The present study aimed to determine the global prevalence of anosmia and dysgeusia in coronavirus disease 2019 (COVID-19) patients and to assess their association with severity and mortality of COVID-19. Moreover, this study aimed to discuss the possible pathobiological mechanisms of anosmia and dysgeusia in COVID-19. : Available articles from PubMed, Scopus, Web of Science, and preprint databases (MedRxiv, BioRxiv, and Researchsquare) were searched on November 10th, 2020. Data on the characteristics of the study (anosmia, dysgeusia, and COVID-19) were extracted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Newcastle-Ottawa scale was used to assess research quality. Moreover, the pooled prevalence of anosmia and dysgeusia were calculated, and the association between anosmia and dysgeusia in presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was assessed using the Z test. : Out of 32,142 COVID-19 patients from 107 studies, anosmia was reported in 12,038 patients with a prevalence of 38.2% (95% CI: 36.5%, 47.2%); whereas, dysgeusia was reported in 11,337 patients out of 30,901 COVID-19 patients from 101 studies, with prevalence of 36.6% (95% CI: 35.2%, 45.2%), worldwide. Furthermore, the prevalence of anosmia was 10.2-fold higher (OR: 10.21; 95% CI: 6.53, 15.96, < 0.001) and that of dysgeusia was 8.6-fold higher (OR: 8.61; 95% CI: 5.26, 14.11, < 0.001) in COVID-19 patients compared to those with other respiratory infections or COVID-19 like illness. To date, no study has assessed the association of anosmia and dysgeusia with severity and mortality of COVID-19. : Anosmia and dysgeusia are prevalent in COVID-19 patients compared to those with the other non-COVID-19 respiratory infections. Several possible mechanisms have been hypothesized; however, future studies are warranted to elucidate the definitive mechanisms of anosmia and dysgeusia in COVID-19. PROSPERO CRD42020223204.
Topics: Anosmia; COVID-19; Dysgeusia; Humans; Incidence
PubMed: 33824716
DOI: 10.12688/f1000research.28393.1